Safety and feasibility of contained uterine morcellation in women undergoing laparoscopic hysterectomy

Table 3 Uterine cancer characteristics, adjuvant therapy and disease status

Characteristic	Uterine cancer (N = 53)
Pre-op Histology (n = 49)
Endometrioid	34 (69.4)
Serous	6 (12.2)
Clear cell	3 (6.1)
Carcinosarcoma	3 (6.1)
Other/unspecified	7 (14.3)
Post-op Histology
Endometrioid	40 (75.5)
Serous	5 (9.4)
Clear cell	1 (1.9)
Carcinosarcoma	7 (13.2)
Grade
1	21 (39.6)
2	15 (28.3)
3	17 (32.1)
Stage
IA	28 (52.8)
IB^a	15 (28.3)
II	1 (1.9)
IIIA	2 (3.8)
IIIC1	3 (5.7)
IIIC2	2 (3.8)
IVB	2 (3.8)
Lymph nodes
Positive	6 (11.32)
Negative	29 (54.7)
Not collected	18 (34.0)
Pelvic Washings
Positive	5 (9.4)
Negative	41 (77.4)
Indeterminate/suspicious	6 (11.3)
Not collected	1 (1.9)
Adjuvant Therapy^b
Radiation	13 (24.5)
Chemotherapy	10 (18.9)
Hormonal	4 (7.6)
Recurrence rate	7 (13.2)
Median time to recurrence (days)	395 [range 128–539]
Status of disease
No evidence of disease	43 (81.1)
Alive with disease^c	3 (5.7)
Died of disease	5 (9.4)
Died of intercurrent disease	1 (1.9)
Died of unknown cause^d	1 (1.9)

Data are n(%) unless otherwise specified
^aDepth of invasion could not be determined in one case and is included in the Stage 1B group
^bChemotherapy: Carboplatin/Taxol (6), Carboplatin/Taxol + Cisplatin (with radiation) (1), Carboplatin/Taxol + Doxil (1); Ifosfamide/Taxol (2). Radiation: vaginal brachytherapy (5), external beam radiation (4), IMRT (2), vaginal brachytherapy + external beam radiation (1). Hormonal: Megace (2), Megace + Tamoxifen (1), Megace + Anastrozole (1)
^c(1) IIIC-2, grade 2 endometrioid, disease-free survival 7.8 months (2) IA, grade 2 endometrioid, disease-free survival 13.2 months (3) IB, grade 3 endometrioid, disease-free survival 4.3 months
^dMost likely this patient died of disease given her disease distribution with distant metastases

ISSN: 2053-6844